NNVC Stock — NanoViricides Inc

NanoViricides Inc (NNVC)

Updated October 16, 2026.

NNVC is a Stock. Its deepest 1-year drawdown was 58.1%.

NanoViricides is a clinical-stage nano-biopharmaceutical company developing antiviral drugs to treat respiratory and other viral infections, including RSV, influenza, COVID-19, shingles, and cold sores; its lead candidate NV-387 has completed early-stage human clinical trials in multiple formulations. The company does not currently distribute to shareholders. This stock appeals to investors with high risk tolerance interested in early-stage biotech development, as the company remains pre-revenue and dependent on successful clinical trials and eventual commercialization.

NNVC performance

Returns are updating. NNVC's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 58.1%.

NNVC key facts

Asset type

Stock

Asset class

Equity

Inception date

08/12/2004

Distribution frequency

None

Last close

$1.38 (as of 2026-10-16)

Market cap

$35,224,500

Average volume

154846.0

Payment date

09/24/2019

Beta

1.791

Payout ratio

0.0%

EPS

$-0.41

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NNVC risks and drawbacks

The deepest 1-year drawdown on record here is 58.1%.

Who may consider NNVC — and who may not

It is a weaker fit for investors who need monthly cash flow (NNVC does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on NNVC

• All tickers starting with N

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions